M
Mana Therapeutics
Innovative cell therapies enhancing cancer treatment efficacy, safety, and accessibility
About Mana Therapeutics
MANA Therapeutics is a biotechnology company focused on developing advanced cell therapies to treat a wide range of liquid and solid tumors. The company operates in the immuno-oncology market, targeting cancer patients who require more effective and safer treatment options. MANA's business model revolves around leveraging proprietary research and clinical trials to create commercial products that improve patient outcomes. The company generates revenue through the development and commercialization of these unique cellular therapies, which are licensed from leading research institutions like the National Hospital CNH and Johns Hopkins Medical Center. MANA's clients include healthcare providers, hospitals, and cancer treatment centers that seek cutting-edge solutions for their patients. Founded in November 2018, MANA Therapeutics is driven by a mission to make advanced cancer treatments more accessible and effective, inspired by the Maori concept of 'mana,' which emphasizes leadership and care for others.
Source: Dealroom company dataAt a glance
- Headquarters
- Kansas City, United States
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- CVCobro Ventures
Series A4 investors entered at this stage
LifeSci Venture Partners
Lightchain Capital
SK Securities- JPJ&W Partners
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mana Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
